n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biosante Drops on Securities Sale

Biosante Drops on Securities Sale

Shares of BioSante Pharmaceuticals fell in late trades after the company announced plans to sell $18 million in securities.

BioSante Pharmaceuticals To Raise $18 Million In Registered Direct Offering

BioSante Pharmaceuticals To Raise $18 Million In Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received commitments from several institutional investors to purchase $18 million of securities in a registered direct offering.

5 Pharma Stocks Trading for Under $2

5 Pharma Stocks Trading for Under $2

These five pharmaceutical stocks trading for under $2 offer the potential for big upside returns in 2011 as the outlook for the drugs sector is strong.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.

BioSante Pharmaceuticals Sells Oncolytic Virus Technology To Cold Genesys, Inc.

BioSante Pharmaceuticals Sells Oncolytic Virus Technology To Cold Genesys, Inc.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced it sold to Cold Genesys, Inc.

BioSante Pharmaceuticals Reports Third Quarter 2010 Financial Results

BioSante Pharmaceuticals Reports Third Quarter 2010 Financial Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter 2010 financial results.

BioSante Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences

BioSante Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Oppenheimer Healthcare Conference being held in New York on November 2-3, 2010, and the Singular Research Conference being held on November 4, 2010 in...

BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll...

BioSante Pharmaceuticals Reaches Key LibiGel® Safety Study Enrollment Target

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study.

BioSante Pharmaceuticals, Inc. To Present At Cancer Immunotherapy Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.

BioSante Pharmaceuticals, Inc. Presents LibiGel® Clinical Study Update At North American Menopause Society Meeting

BioSante Pharmaceuticals, Inc. Presents LibiGel® Clinical Study Update At North American Menopause Society Meeting

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) presented a LibiGel clinical study update at the 21 st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and...

BioSante Pharmaceuticals, Inc. To Present LibiGel® Clinical Trial Update At North American Menopause Society Meeting

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will present a LibiGel clinical trial update at the 21 st Annual Meeting of The North American Menopause Society (NAMS) being held from October 6-9,...

BioSante Pharmaceuticals To Present At The Bio Investor Forum

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Bio Investor Forum to be held on October 5-6, 2009 at the Palace Hotel in San Francisco, California.

BioSante Pharmaceuticals, Inc. To Present At The JMP Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010.

BioSante Pharmaceuticals, Inc. To Present At The Rodman & Renshaw Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Healthcare Conference being held in the New York Palace Hotel, New York City from September 12-15, 2010.

BioSante Pharmaceuticals Reports Second Quarter 2010 Financial Results

BioSante Pharmaceuticals Reports Second Quarter 2010 Financial Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its financial results for the second quarter of 2010.

BioSante Pharmaceuticals Announces Initiation Of LibiGel® Study To Evaluate Its Effect On Cognitive Function In Women

BioSante Pharmaceuticals Announces Initiation Of LibiGel® Study To Evaluate Its Effect On Cognitive Function In Women

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the initiation of a LibiGel ® (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women.

BioSante Pharmaceuticals Announces Positive Clinical Results In Pill-Plus™ Oral Contraceptive Study

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) announced today positive results in a Phase II study of the Pill-Plus “triple hormone” oral contraceptive (OC).

BioSante Pharmaceuticals Added To Russell 3000® Index

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.

BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering To Fund LibiGel® For Female Sexual Dysfunction

BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering To Fund LibiGel® For Female Sexual Dysfunction

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering.

BioSante Pharmaceuticals To Raise $15 Million In Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering.

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Clinical Program

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel ® Cardiovascular (CV) and Breast Cancer Safety Study unanimously ...

BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin Has No Impact On LibiGel®

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no...

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Update At ENDO Annual Meeting

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Update At ENDO Annual Meeting

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

Crystallex International, Sprint Nextel: Early Volume Plays

Several stocks trading near $5, including Crystallex International, were poised to move on above-average volume during Monday's session.

BioSante Announces FDA Orphan Drug Designation For GVAX Chronic Myeloid Leukemia Cancer Vaccine

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA’s Office of Orphan Products ...

BioSante Pharmaceuticals, Inc. To Present At The Annual Needham Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 9 th Annual Needham Healthcare Conference being held in the New York Palace Hotel, New York City from June 9-10, 2010.

BioSante Pharmaceuticals, Inc. To Present At The Annual Needham Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Annual Needham Healthcare Conference to be held in the New York Palace Hotel, New York City from June 9-10, 2010.

BioSante Pharmaceuticals Announces Novartis’ Successful Use Of 2A/Furin Technology In Their Antibody Development Platform

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the...

Stock Offerings: FirstMerit Corp.

FirstMerit Corp. shares fell Monday after the company announced a a $315 million common stock offering.